Insights

Perspective, tips, and resources for moving health forward

All Insights Health Systems Pharmacies Physician Practices Manufacturers Animal Health

AmerisourceBergen

Opportunities and pain points for CGT innovation and market access

Lung-I Cheng

Biopharma Services

February 2024

Manufacturers

Pharma in the field: Barrett's story

AmerisourceBergen

February 2024

Manufacturers

Case Study: Improve the effectiveness of field reimbursement support

AmerisourceBergen

January 2024

Manufacturers

Work worth doing: Innovative field solutions

AmerisourceBergen

December 2023

Manufacturers

When supplementing your field reimbursement and access team benefits you most

AmerisourceBergen

December 2023

handshake between vet and business partner

Manufacturers

Essential skills for outsourced field solutions teams

AmerisourceBergen

November 2023

Manufacturers

3 reasons biopharma uses shared resources for its field support team

AmerisourceBergen

November 2023

Manufacturers

Checklist: Why you need a learning solutions partner with market access and reimbursement expertise

AmerisourceBergen

October 2023

Young, Black, female employee looks at a clipboard

Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

AmerisourceBergen

October 2023

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Corey Ford, MHA

August 2023

Manufacturers

Pre-launch checklist: What to look for in a commercialization partner

AmerisourceBergen

June 2023

Reimbursement considerations for home infusions

Xcenda

June 2023

Manufacturers

How to forge stronger working relationships with payers

Warren Dunn

AmerisourceBergen

March 2023

Close-up of two business women shaking hands

Manufacturers

HTA Quarterly | Spring 2023

Xcenda

February 2023

Manufacturers

The essential guide to drug commercialization

AmerisourceBergen

February 2023

Manufacturers

HTA Quarterly | Summer 2023

Xcenda

November 2022

Manufacturers

HTA Quarterly | Winter 2022

Xcenda

October 2022

Manufacturers

Evaluating alternative revolutionary reimbursement models to craft a sustainable business model for cell and gene therapies

David Senior

AmerisourceBergen

October 2022

Manufacturers

Improve outcomes and reduce costs for emerging therapies

AmerisourceBergen

October 2022

Manufacturers

Maintain an agile copay program in a changing policy environment

AmerisourceBergen

September 2022

Elevate Provider Network fights to prohibit GER, BER, and DIR Recoupments

Peter Kounelis; Beth Lea; Shaun Henry; Tracy Armstrong

AmerisourceBergen

August 2022

Cropped shot of a pharmacist using a digital tablet in a chemist

Manufacturers

Innovative agreements: Exploring alternative payment models

AmerisourceBergen

July 2022

Manufacturers

Navigating reimbursement and access challenges for novel cell and gene therapies

Amanda OHora

July 2022

Manufacturers

Differentiate your product with FormularyDecisions®

Xcenda

April 2022

Differentiate your product with FormularyDecisions

Pharmacies

Five benefits of an innovative PSAO

Gold Eneyo, PharmD; Phyllis Houston, MSOL ; Peter Kounelis, R.Ph.

AmerisourceBergen

March 2022

Manufacturers

Commercializing cell and gene therapies in Canada

AmerisourceBergen

February 2022

Cell and gene therapies are currently at the forefront of scientific innovation. They hold great promise for patients suffering from a range of serious ailments.

Pharmacies

Podcast: Investing in independents

Peter Kounelis, R.Ph.

AmerisourceBergen

January 2022

Pharmacies

Executive Q&A: Investing in independent pharmacy

AmerisourceBergen

January 2022

Manufacturers

Working with government entities to advance access, affordability, and supply chain stability

AmerisourceBergen

December 2021

Manufacturers

Building your field reimbursement and access team: The translational experience and skills that matter most

AmerisourceBergen

September 2021

Manufacturers

eBook: Bringing innovation to market with digital therapeutics

Lash Group

August 2021

Pharmacies

What pharmacies should know about DIRs, GERs, and BERs

Tim Jones; Beth Lea

AmerisourceBergen

August 2021

Manufacturers

Digital innovation in patient support

Innomar Strategies

August 2021

Manufacturers

What manufacturers need to know about reimbursement and patient support for cell and gene therapies

Ana Stojanovska; Myra Reinhardt

Biopharma Services

July 2021

Manufacturers

Navigating the payer landscape for digital therapeutics

Lash Group

June 2021

Manufacturers

Patient support for digital therapeutics: Do's and don'ts for designing your program

Lash Group

June 2021

Manufacturers

Work worth doing: FormularyDecisions

Laurie Fazio

Xcenda

May 2021

Manufacturers

How to make the most of integrated commercialization solutions

Glen Martin

AmerisourceBergen

March 2021

Manufacturers

Buy-and-bill vs. self-administered: Field services remove barriers across access points

Rod Bryant, MS; MarSha Lewers

March 2021

Physician Practices

Healthcare payer trends in 2021

Christie Smith; Kristy McGowan

March 2021

Manufacturers

Webinar: uptake or heartbreak with biosimilars? Progress and perspectives

AmerisourceBergen

February 2021

Manufacturers

Checklist: Four things to look for in a field services partner

Xcenda

February 2021

Manufacturers

Launching field services in the midst of COVID-19

Xcenda

February 2021

Manufacturers

Case study: an innovative field reimbursement program expands patient access

Xcenda

January 2021

Manufacturers

Evaluating the modern field reimbursement and access program: key considerations

Xcenda

December 2020

Manufacturers

Pharma in the field: Heather's story

Xcenda

December 2020

Manufacturers

Webinar: the growing utilization of copay accumulator programs

Corey Ford, MHA; Dale Hanna

December 2020

Manufacturers

Pharma in the field: Ashley's story

Xcenda

November 2020

Manufacturers

Pharma in the field: Tierra's story

Xcenda

November 2020

Health Systems

Biosimilars: Patents, policy, and reimbursement

Sean McGowan; Steve Miller; David Senior

AmerisourceBergen

October 2020

Case study: Gaining payer attention through digital innovation

Xcenda

September 2020

businessman with laptop reviewing a dashboard

Manufacturers

Solving access, reimbursement, and PAP awareness problems

Xcenda

August 2020

Male doctor speaking to patient on a tablet

Physician Practices

How to thrive with telemedicine

IntrinsiQ Specialty Solutions

August 2020

Manufacturers

Distant But Engaged: Transitioning to Virtual Training

Xcenda

May 2020

Manufacturers

Video: Removing Barriers for Biosimilars

AmerisourceBergen

February 2020

Manufacturers

How Digital Innovation Drives Improved Market Access Strategies

Xcenda

July 2019

In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?

Manufacturers

Managing the Growing Expansion of Copay Accumulators

Corey Ford, MHA

March 2019

Manufacturers

Medicare Part B: Do Providers Choose Treatment Based on Payment?

Xcenda

January 2019

What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.

Pharmacies

Delivering Care Beyond Prescriptions: A Marketplace Opportunity for Independent Pharmacies

Brian Nightengale

AmerisourceBergen

December 2018

The high-touch, high-quality, personalized care independent pharmacies provide creates a unique value proposition in a healthcare market where more chronically ill patients need accessible care. As payers are prioritizing improved patient outcomes and a reduction in overall healthcare costs, they need to also consider new reimbursement models for these pharmacy services, a framework under which independent pharmacies are uniquely positioned to excel.

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Ana Stojanovska

Biopharma Services

June 2018

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Ana Stojanovska

Biopharma Services

June 2018

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

Manufacturers

Insight Series: Value of Patient Support Programs for Specialty Medications in Canada

Innomar Strategies

May 2018

Manufacturers

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

AmerisourceBergen

April 2018

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Manufacturers

Rethinking Reimbursement and Patient Support Following Medical Innovation

AmerisourceBergen

January 2018

How can manufacturers approach reimbursement and patient support for cell and gene therapies and other medical innovations?

Manufacturers

Information Exchange With Payers and Providers

AmerisourceBergen

January 2018

What information do payers and providers want from pharma?

Manufacturers

What Do Payers Think About Digital Health Technologies

AmerisourceBergen

September 2017

How are payers thinking about apps, wearables and other digital health technologies?

Manufacturers

The Route to Market Access in Canada

Innomar Strategies

September 2017

Understanding the unique considerations for reimbursement in the Canadian pharmaceutical market.

Manufacturers

Commercializing Cell and Gene Therapies

AmerisourceBergen

July 2017

Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.

Physician Practices

Plugging Profit Leaks

Alana Vaughn

ION Solutions

November 2016

Like a slowly dripping faucet or an improperly insulated window, gaps and inefficiencies in a business allow profits to seep out over time. Even one leak—while seemingly small—can have damaging effects on a company’s financial health. Oncology practices are no different.